Preface to the tenth edition


Welcome to Part A of the 10th edition of the BSAVA Small Animal Formulary, providing up-to-date information about the drugs used for cats and dogs. I would like to start by thanking Professor Ian Ramsey for his tremendous work over the previous four editions of the Formulary, cementing this book as a superbly useful tool for small animal veterinary surgeons.

In revising the latest edition, several new drug monographs have been added, including additional chemotherapeutic agents. The introduction of bullet points within the description of uses should highlight where certain drugs have multiple, reported indications.

Through ongoing veterinary research data relating to drug use, adverse reactions and drug interactions is developed regularly; veterinary surgeons and nurses are reminded to also consult other sources when confronted with a medication with which they are unfamiliar. As well as the cited references, textbooks such as the excellent series of manuals published by the BSAVA can provide a wealth of pertinent information.

This year, the guidelines on antibacterial use have been adapted to reflect the 2018 launch of the PROTECT ME initiative. Antimicrobial resistance is likely to represent a major challenge to human and animal healthcare in this new decade. Veterinary surgeons have a responsibility to pursue rational antibacterial use at all times and are encouraged to refer to the latest recommendations regarding the need for and selection of antibacterial medication for any particular condition.

An illustrative flowchart has been added to the information regarding the prescribing cascade following the clarifications published by the Veterinary Medicines Directorate in 2019. Veterinary surgeons are reminded of the need to ensure that their prescribing policies and practices comply with existing guidelines and legislation. The Formulary provides information about many drugs not authorized for use in animals. Authorized products should be considered first for every patient; when such products are not available, or not clinically suitable, unauthorized medicines may be used in accordance with the cascade. In such cases, a clear clinical justification, made on an individual basis, should be recorded in the clinical notes or on the prescription.

I would like to thank the Editorial Panel members for their efforts on this edition. I would also like to thank Alessandra Mathis, Jacques Ferreira, Gwen Covey-Crump, Tim Nuttall, Charlotte Robinson and James Swann for their invaluable advice with particular sections. My gratitude also goes to the editorial team members at BSAVA for their generous and enthusiastic assistance. I would welcome all comments and feedback from BSAVA members on this latest edition of the .

Fergus Allerton

January 2020

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error